Jean-Philippe Lanoix

Prof. Dr. Jean-Philippe Lanoix


Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 December 2020 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
PDF file
DRDalin Rifat
Dalin Rifat
SLSi-Yang Li
Si-Yang Li
TIThomas Ioerger
Thomas Ioerger
KSKeshav Shah
Keshav Shah
JLJean-Philippe Lanoix
Jean-Philippe Lanoix
ENEric Nuermberger
Eric Nuermberger
The nitroimidazole prodrugs delamanid and pretomanid comprise one of only two new antimicrobial classes approved to treat tuberculosis (TB) in 50 years. Prior in vitro studies suggest a relatively low barrier to nitroimidazole resistance in Mycobacterium tuberculosis , but clinical evidence is limited to date. We selected pretomanid-resistant M. tuberculosis mutants in two mouse models of TB using a range of pretomanid doses. The frequency of spontaneous resistance was approximately 10 −5 CFU.

1 February 2016 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
PDF file
JLJean-Philippe Lanoix
Jean-Philippe Lanoix
TIThomas Ioerger
Thomas Ioerger
AOAimee Ormond
Aimee Ormond
FKFirat Kaya
Firat Kaya
JSJames Sacchettini
James Sacchettini
ENEric Nuermberger
Eric Nuermberger
Pyrazinamide (PZA) is one of only two sterilizing drugs in the first-line antituberculosis regimen. Its activity is strongly pH dependent; the MIC changes by several orders of magnitude over a range of pH values that may be encountered in variousin vivocompartments. We recently reported selective inactivity of PZA in a subset of C3HeB/FeJ mice with large caseous lung lesions. In the present study, we evaluated whether such inactivity was explained by poor penetration of PZA into such lesions or selection of drug-resistant mutants. Despite demonstrating similar dose-proportional PZA exposures in plasma, epithelial lining fluid, and lung lesions, no dose response was observed in a subset of C3HeB/FeJ mice with the highest CFU burden. Although PZA-resistant mutants eventually replaced the susceptible bacilli in BALB/c mice and in C3HeB/FeJ mice with low total CFU burdens, they never exceeded 1% of the total population in nonresponding C3HeB/FeJ mice. The selective inactivity of PZA in large caseous lesions of C3HeB/FeJ mice is best explained by the neutral pH of liquefying caseum.

29 September 2020 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
PBPierre-Yves Boelle
Pierre-Yves Boelle
TDTristan Delory
Tristan Delory
XMXavier Maynadier
Xavier Maynadier
CJcecile janssen
cecile janssen
RPrenaud piarroux
renaud piarroux
Olivier RobineauOlivier Robineau
Olivier Robineau
Describing the characteristics of COVID-19 patients in the hospital is of importance to assist in the management of hospital capacity in the future. Here, we analyze the trajectories of 1321 patients admitted to hospitals in northern and eastern France. We found that the time from onset to hospitalization decreased with age, from 7.3 days in the 20–65 year-olds to 4.5 in the >80 year-olds (p < 0.0001). Overall, the length of stay in the hospital was 15.9 days, and the death rate was 20%. One patient out of four was admitted to the intensive care unit (ICU) for approximately one month. The characteristics of trajectories changed with age: fewer older patients were admitted to the ICU and the death rate was larger in the elderly. Admission shortly after onset was associated with increased mortality (odds-ratio (OR) = 1.8, Confidence Interval (CI) 95% [1.3, 2.6]) as well as male sex (OR = 2.1, CI 95% [1.5, 2.9]). Time from admission within the hospital to the transfer to ICU was short. The age- and sex-adjusted mortality rate decreased over the course of the epidemic, suggesting improvement in care over time. In the SARS-CoV-2 epidemic, the urgent need for ICU at admission and the prolonged length of stay in ICU are a challenge for bed management and organization of care.

27 June 2011 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
JLJean-Philippe Lanoix
Jean-Philippe Lanoix
EPEmilie Pluquet
Emilie Pluquet
FLFrancois Xavier Lescure
Francois Xavier Lescure
HBHoucine Bentayeb
Houcine Bentayeb
ELEmmanuelle Lecuyer
Emmanuelle Lecuyer
YDYoucef Douadi
Youcef Douadi
The chemotherapy used to treat lung cancer causes febrile neutropenia in 10 to 40% of patients. Although most episodes are of undetermined origin, an infectious etiology can be suspected in 30% of cases. In view of the scarcity of data on lung cancer patients with febrile neutropenia, we performed a retrospective study of the microbiological characteristics of cases recorded in three medical centers in the Picardy region of northern France.

1 February 2016 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
PDF file
JLJean-Philippe Lanoix
Jean-Philippe Lanoix
Fabrice BetoudjiFabrice Betoudji
Fabrice Betoudji
ENEric Nuermberger
Eric Nuermberger
Pyrazinamide (PZA) is a key sterilizing drug in first-line tuberculosis (TB) regimens and exerts its activity entirely during the first 2 months in human infections. We recently described the reduced activity of PZA in C3HeB/FeJ mice with large caseous tubercles due to neutral pH. Here, we aimed to determine the contribution of PZA to the sterilizing activity of the first-line TB regimen in C3HeB/FeJ and BALB/c mice. Three regimens were compared (in combinations: R, rifampin; H, isoniazid; E, ethambutol; Z, pyrazinamide; with numbers indicating the treatment duration, in months): 2RHEZ/4RH, 2RHE/4RH, and 2RHEZ/4RHZ. Lung CFU counts were assessed after 0 and 2 months of treatment, and relapse rates were assessed 3 months after 3, 4.5, and 6 months of treatment. The relapse rates after 3 months of treatment were 53% and 95% in C3HeB/FeJ mice receiving 2RHEZ/1RH and 2RHE/1RH, respectively, and 67%, 100%, and 80% in BALB/c receiving 2RHEZ/1RH, 2RHE/1RH, and 2RHEZ/1RHZ, respectively. The relapse rates after 4.5 months of treatment were 32%, 20%, and 0% in C3HeB/FeJ mice receiving 2RHEZ/2.5RH, 2RHE/2.5RH, and 2RHEZ/2.5RHZ, respectively, and 0% and 67% in BALB/c receiving 2RHEZ/2.5RH and 2RHE/2.5RH, respectively. The month-6 relapse rates were 0%, 13%, and 0% in C3HeB/FeJ mice given 2RHEZ/4RH, 2RHE/4RH, and 2RHEZ/4RHZ, respectively, and 7% in BALB/c mice receiving 2RHE/4RH. The addition of PZA shortens the duration of treatment needed to prevent relapse in both mouse strains. However, while its contribution is limited to the first 2 months of treatment in BALB/c mice, continuing PZA beyond the first 2 months is beneficial in C3HeB/FeJ mice by preventing relapse among those with the highest disease burden.

21 April 2020 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
JLJean-Philippe Lanoix
Jean-Philippe Lanoix
CJCédric Joseph
Cédric Joseph
FPFrançois Peltier
François Peltier
SCSandrine Castelain
Sandrine Castelain
CAClaire Andréjak
Claire Andréjak
Infections with nontuberculous mycobacteria (NTM) have a poor prognosis in patients with underlying respiratory diseases. Clofazimine (CFZ) showed both experimental and clinical promising results against clinically relevant NTM. However, there are no data on CFZ in combination with the current recommended treatment; therefore, we aimed to study its in vivo activity in an aerosol mouse model of Mycobacterium avium . In an aerosol infection BALB/c mouse model using M. avium strain Chester, we treated 58 mice with four combinations of rifampin (RIF) at 10 mg/kg, CFZ at 25 mg/kg, and clarithromycin (CLR) and ethambutol (EMB) at 100 mg/kg.